Tedizolid (TR-701): a new oxazolidinone with enhanced potency.
BACKGROUND
Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid.


METHODS
This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed.


CONCLUSIONS
Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.
American University of Beirut Medical Center, Beirut, Lebanon. zk10@aub.edu.lb
Zeina A
ZA
Kanafani
G Ralph
GR
Corey
D000818:Animals; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D023303:Oxazolidinones / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D011500:Protein Synthesis Inhibitors / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013777:Tetrazoles / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D011500:Protein Synthesis Inhibitors; D013777:Tetrazoles